Will Wave Life Sciences announce a new pharma partnership by March 31, 2025? | Binary | | | 2 months ago | |
New hypoparathyroidism treatment announced by another company by end of 2024? | Binary | | | 4 months ago | |
Major pharmaceutical company to acquire Ascendis Pharma by end of 2024? | Categorical | | | 4 months ago | |
Will Wave Life Sciences stock increase by 20% or more by December 31, 2024? | Binary | | | 2 months ago | |
Will Takeda announce a new Huntington's disease collaboration by June 30, 2025? | Binary | | | 2 months ago | |
Which biotech company will Takeda invest in by June 30, 2025? | Categorical | | | 2 months ago | |
Ascendis Pharma stock price increase by more than 20% by end of August 2024? | Binary | | | 4 months ago | |
FDA warnings or recalls for YORVIPATH by end of 2024? | Binary | | | 4 months ago | |
YORVIPATH sales over $100 million by end of 2024? | Binary | | | 4 months ago | |
Percentage increase in Ascendis Pharma's stock price by end of August 2024? | Categorical | | | 4 months ago | |
Ascendis Pharma stock increase by at least 20% by end of 2024? | Binary | | | 4 months ago | |
What will be Wave Life Sciences' next strategic focus area by June 30, 2025? | Categorical | | | 2 months ago | |
What condition will Wave Life Sciences' new drug candidate target by September 30, 2025? | Categorical | | | 2 months ago | |
Main competitor for Ascendis Pharma in hypoparathyroidism treatment by end of 2024? | Categorical | | | 4 months ago | |
Market share of YORVIPATH in US hypoparathyroidism treatment market by end of 2024? | Categorical | | | 4 months ago | |
Percentage increase in Ascendis Pharma's stock by end of 2024? | Categorical | | | 4 months ago | |
Company with highest market share in hypoparathyroidism treatments by end of 2024? | Categorical | | | 4 months ago | |
FDA safety warning for Ascendis Pharma's YORVIPATH by end of 2024? | Binary | | | 4 months ago | |
